ConductScience.org, home

Paper21106989

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.

Ju W and 12 others. Blood, 2011. Cited by 61 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Papers, record 21106989. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21106989

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
PubMed
Journal
Blood
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
61
iCite
Relative citation ratio, by iCite
1.46
iCite
Revised in PubMed
2021-10-20
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ju WWei
2Zhang MMeili
3Jiang JKJian-kang
4Thomas CJCraig J
5Oh UUnsong
6Bryant BRBonita R
7Chen JJing
8Sato NNoriko
9Tagaya YYutaka
10Morris JCJohn C
11Janik JEJohn E
12Jacobson SSteven
13Waldmann TAThomas A

Source PubMed

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Janus Kinase 3Major topic
Leukemia-Lymphoma, Adult T-CellMajor topic
Paraparesis, Tropical SpasticMajor topic
PyrimidinesMajor topic
PyrrolesMajor topic
T-LymphocytesMajor topic
Adult
Animals
Cell Line, Tumor
Cell Proliferation
Cytokines
Enzyme Activation
Humans
In Vitro Techniques
Interleukin-15
Leukemia, Experimental
Mice
Mice, Inbred NOD
Mice, SCID
Mice, Transgenic
Phosphorylation
Piperidines
STAT5 Transcription Factor
Signal Transduction

Source PubMed

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
UL1 RR031990NCRR NIH HHSUnited StatesUL1RR031990PubMed and NIHNIH RePORTER
Intramural NIH HHSUnited StatesPubMedPubMed
ZIANS002817NIHNIH RePORTER
ZIANS003040NIHNIH RePORTER
ZIASC004002NIHNIH RePORTER
ZIBHG200319NIHNIH RePORTER

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in21,310,928JAK blockade and HTLV.https://conductscience.org/library/papers/21310928

Source PubMed

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111,717,409IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients.Proc Natl Acad Sci U S A2001https://conductscience.org/library/papers/11717409PubMed
215,342,663Clinical trials for malignant lymphoma in Japan.Jpn J Clin Oncol2004https://conductscience.org/library/papers/15342663PubMed
38,070,818The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c.Immunol Rev1994https://conductscience.org/library/papers/8070818PubMed
415,371,489The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.J Leukoc Biol2004https://conductscience.org/library/papers/15371489PubMed
58,782,447STATs and cytokine specificity.Nat Med1996https://conductscience.org/library/papers/8782447PubMed
616,868,550The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.Nat Rev Immunol2006https://conductscience.org/library/papers/16868550PubMed
79,391,124Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.Proc Natl Acad Sci U S A1997https://conductscience.org/library/papers/9391124PubMed
816,155,604Molecular mechanisms of cellular transformation by HTLV-1 Tax.Oncogene2005https://conductscience.org/library/papers/16155604PubMed
911,046,040Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.J Immunol2000https://conductscience.org/library/papers/11046040PubMed
1016,314,797Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts.Transplantation2005https://conductscience.org/library/papers/16314797PubMed
1119,053,756Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).J Med Chem2008https://conductscience.org/library/papers/19053756PubMed
121,751,370Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).Br J Haematol1991https://conductscience.org/library/papers/1751370PubMed
1311,053,100Advances in interleukin 2 receptor targeted treatment.Ann Rheum Dis2000https://conductscience.org/library/papers/11053100PubMed
1415,090,550Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation.J Biol Chem2004https://conductscience.org/library/papers/15090550PubMed
152,871,307HTLV-I associated myelopathy, a new clinical entity.Lancet1986https://conductscience.org/library/papers/2871307PubMed
167,604,283Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.Science1995https://conductscience.org/library/papers/7604283PubMed
1718,785,636Tracking antigen-driven responses by flow cytometry: monitoring proliferation by dye dilution.Cytometry A2008https://conductscience.org/library/papers/18785636PubMed
187,760,890Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.N Engl J Med1995https://conductscience.org/library/papers/7760890PubMed
197,481,769Defective lymphoid development in mice lacking Jak3.Science1995https://conductscience.org/library/papers/7481769PubMed
2011,156,399IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.Cancer Res2000https://conductscience.org/library/papers/11156399PubMed

See all 46 references

Cited by47

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.

PMIDTitleJournalYearIn PapersSource
42,534,713Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions - A Narrative Review.Health Sci Rep2026https://conductscience.org/library/papers/42534713PubMed
42,055,322The tumor suppressor NDRG2 recruits protein phosphatase 2A to suppress STAT5 phosphorylation in adult T-cell leukemia/lymphoma.J Biol Chem2026https://conductscience.org/library/papers/42055322PubMed
37,221,459Immunopathogenesis of viral infections in neurological autoimmune disease.BMC Neurol2023https://conductscience.org/library/papers/37221459PubMed
37,205,097The potential of regulatory T cell-based therapies for alopecia areata.Front Immunol2023https://conductscience.org/library/papers/37205097PubMed
37,153,603The role of interleukin-15 in the development and treatment of hematological malignancies.Front Immunol2023https://conductscience.org/library/papers/37153603PubMed
35,406,451Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.Cancers (Basel)2022https://conductscience.org/library/papers/35406451PubMed
35,100,463Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.Cancer Sci2022https://conductscience.org/library/papers/35100463PubMed
33,837,058Effect of Teriflunomide on Cells From Patients With Human T-cell Lymphotropic Virus Type 1-Associated Neurologic Disease.Neurol Neuroimmunol Neuroinflamm2021https://conductscience.org/library/papers/33837058PubMed
33,491,334Tofacitinib overcomes an IFNγ-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2/ad.Thorac Cancer2021https://conductscience.org/library/papers/33491334PubMed
33,129,109Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia.Transl Oncol2021https://conductscience.org/library/papers/33129109PubMed
32,952,617Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.Ther Adv Musculoskelet Dis2020https://conductscience.org/library/papers/32952617PubMed
32,707,925Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates.Molecules2020https://conductscience.org/library/papers/32707925PubMed
32,508,847Th9 Cell Differentiation and Its Dual Effects in Tumor Development.Front Immunol2020https://conductscience.org/library/papers/32508847PubMed
31,821,442Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.J Exp Med2020https://conductscience.org/library/papers/31821442PubMed
31,105,674Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis.Front Microbiol2019https://conductscience.org/library/papers/31105674PubMed
30,854,19440 years of the human T-cell leukemia virus: past, present, and future.F1000Res2019https://conductscience.org/library/papers/30854194PubMed
30,353,031IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability.Leukemia2019https://conductscience.org/library/papers/30353031PubMed
29,867,836Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.Front Microbiol2018https://conductscience.org/library/papers/29867836PubMed
29,682,185STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.Oncotarget2018https://conductscience.org/library/papers/29682185PubMed
29,434,279Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.Leukemia2018https://conductscience.org/library/papers/29434279PubMed

See all 47 cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL153,600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene
IL23,558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
IL93,578PubTator's text mininghttps://conductscience.org/library/genes/3578NCBI Gene
JAK33,718PubTator's text mininghttps://conductscience.org/library/genes/3718NCBI Gene
STAT5A6,776PubTator's text mininghttps://conductscience.org/library/genes/6776NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21106989

GET https://conductscience.org/api/papers/v1/21106989/references?page=2